title: The efficiency of humoral immune transfer depends on both the graft and the immunosuppressive treatment.
abstract: The present study was designed to compare the efficiency of adoptive transfer of humoral immunity after liver, kidney, and heart transplantation in relation to the number of passenger lymphocytes, and to estimate the risk of a detrimental effect and the chance of a beneficial effect. Hepatitis B virus surface-antigen-vaccinated brown Norway rats (BNs) and AxC 9935 Irish (ACI rats) served as donors, and naïve Lewis (LEW) rats as recipients. The liver grafts contained 100 times more passenger lymphocytes than heart grafts, and the kidney grafts approximately ten times more, indicated by monoclonal CD45 antibody staining. Transient anti-HBs immunity did occur after transplantation of all three organ grafts. In all rejecting groups, the serum recipient-to-donor anti-HBs titer ratio (R/D ratio) was below 0.10%, with heart recipients showing half the level (0.05%) of liver recipients (0.09%). Under immunosuppression, R/D ratio doubled in liver or kidney recipients, but remained unaffected in heart recipients. Immune transfer was most efficient in immune-suppressed liver recipients in the spontaneously tolerant strain combination as indicated by a significantly higher R/D ratio (0.32%) and a longer titer persistence (up to 9 weeks) than in all other groups. Therefore, mainly liver and kidney graft recipients carry a risk, but also a chance of benefiting from the transfer of donor-derived immunity.
authors.affiliation: Klinik und Poliklinik für Allgemeine und transplantationschirurgie, Universitätsklinikum Essen, Hufelandstrase 55, 45122, Essen, Germany. uta.dahmen@uni-essen.de
authors.forename: Uta
authors.initials: U
authors.lastname: Dahmen
authors.forename: Jun
authors.initials: J
authors.lastname: Li
authors.forename: Yi
authors.initials: Y
authors.lastname: Gu
authors.forename: Lothar
authors.initials: L
authors.lastname: Doebel
authors.forename: Li Ming
authors.initials: LM
authors.lastname: Fan
authors.forename: Susanne
authors.initials: S
authors.lastname: Polywka
authors.forename: Olaf
authors.initials: O
authors.lastname: Dirsch
authors.forename: Christoph E
authors.initials: CE
authors.lastname: Broelsch
mesh_terms: D000818:Animals; D000917:Antibody Formation; D016027:Heart Transplantation / Q000276:immunology*; D007150:Immunohistochemistry; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D018799:Intercellular Adhesion Molecule-1 / Q000032:analysis; D016030:Kidney Transplantation / Q000276:immunology*; D016031:Liver Transplantation / Q000276:immunology* / Q000473:pathology; D051381:Rats; D011912:Rats, Inbred ACI; D011914:Rats, Inbred BN; D011917:Rats, Inbred Lew; D014181:Transplantation Immunology / Q000276:immunology*; D014184:Transplantation, Homologous
chemical_list: D007166:Immunosuppressive Agents; D018799:Intercellular Adhesion Molecule-1